

Structurally inherent antigenic sites

Localization of the antigenic sites of the α -chain of human haemoglobin in three host species by a comprehensive synthetic approach

A. Latif KAZIM and M. Zouhair ATASSI*

Department of Immunology, Mayo Medical School, Rochester, MN 55905, U.S.A.

(Received 11 August 1981/Accepted 22 December 1981)

The antigenic structure of the α -chain of human haemoglobin was studied by a synthetic approach consisting of the synthesis of a series of consecutive overlapping peptides that together systematically represent the entire primary structure of the protein. This approach enabled the identification of a full profile of immunochemically active α -chain peptides and the localization of its major 'continuous' antigenic sites. Antibodies to haemoglobin raised in each of three different species (goat, rabbit and mouse) recognize similar sites on the α -chain. Further, the molecular locations of these sites coincide with α -chain regions extrapolated from antigenic sites of the conformationally similar myoglobin molecule. These findings support our earlier proposed concept of 'structurally inherent antigenic sites', namely that antigenicity is conferred on certain surface regions of proteins by virtue of their three-dimensional locations. Thus the antigenic sites of conformationally related proteins are likely to have similar molecular locations.

Previously we reported the prediction and confirmation by synthesis (Kazim & Atassi, 1977a) of two antigenic sites on human haemoglobin, one each on its α - and β -chains, by extrapolation of the three-dimensional location of an antigenic site of sperm-whale myoglobin (Atassi, 1975). The finding that antigenic sites on immunochemically unrelated members of the same protein family can exist in conformationally homologous regions gave considerable support to our proposal of 'structurally inherent antigenic sites' (Atassi & Kazim, 1978), namely that the antigenicity of protein antigenic sites is derived largely from their conformational locations in the respective protein chains (Atassi & Kazim, 1978). Although the individual α - and β -subunits of haemoglobin (Hb) have similar overall tertiary structures to myoglobin (Mb), its tetrameric subunit structure endows Hb with unique conformational properties that contrast with those of the monomeric Mb molecule (Perutz *et al.*, 1968). Therefore the presence of structurally inherent antigenic sites on Hb and Mb do not preclude these proteins from having antigenic sites at dissimilar three-dimensional positions.

Abbreviations used: Hb, haemoglobin; Mb, myoglobin; IgG, immunoglobulin G.

* To whom correspondence should be addressed.

In order to identify other continuous (see the Discussion section for explanation of nomenclature) antigenic sites on Hb, we devised (Kazim & Atassi, 1980b) a novel and comprehensive synthetic approach that would localize antigenic sites occurring throughout the α - and β -chains of the Hb molecule. This approach consists of studying the immunochemical activities of a series of overlapping synthetic peptides that encompass the entire primary structure of the protein chain (Fig. 1). The rationale for this approach is presented in detail in the Discussion. In a preliminary communication (Kazim & Atassi, 1980b) we reported the application of this strategy to the α -chain of Hb that enabled identification of the full profile of immunochemically active synthetic peptides recognized by goat antisera to Hb. In the present paper we report additional details of the synthesis of these peptides, our findings with antisera to Hb raised in other animal species, and the localization of the antigenic sites to fairly narrow regions of the α -chain.

Experimental

Human adult Hb (cyanmet-HbA) was prepared by chromatography on CM-cellulose as previously described (Atassi, 1964). The α - and β -chains of Hb were obtained by treatment of carbonmonoxy-Hb

with *p*-hydroxymercuribenzoate (Bucci & Fronticelli, 1965), followed by repeated chromatography on CM-cellulose or DEAE-cellulose (Geraci *et al.*, 1969) until they were homogeneous by polyacrylamide-gel electrophoresis. After isolation of the subunits their thiol groups were regenerated with mercaptoethanol (Geraci *et al.*, 1969).

Solid-phase synthesis (Merrifield, 1963) of the α -chain peptides (see Fig. 1), from the known primary structure of Hb (Braunitzer *et al.*, 1961; Hill & Konigsberg, 1962), was performed by procedures similar to those described by Stewart & Young (1969) and as employed for the synthesis of myoglobin antigenic sites (Koketsu & Atassi, 1973, 1974). After cleavage from the resin and removal of the amino acid side-chain protecting groups, the peptides were purified by ion-exchange chromatography on CM-Sephadex (C-50) or DEAE-Sephadex (A-50) as previously described (Koketsu & Atassi, 1973, 1974). The purity of the peptides thus obtained was examined by high-voltage paper electrophoresis. The compositions of each peptide was verified by amino acid analysis (Atassi & Saplin, 1968). For the determination of tryptophan, peptide 11–25 was hydrolysed with 3M-toluene-*p*-sulphonic acid containing 0.2% 3-(2-aminoethyl)-indole, as described by Liu & Chang (1971).

Proteins and peptides were coupled to CNBr-activated Sepharose CL-4B (March *et al.*, 1974). The amounts of proteins and peptides used in the coupling reactions were 3 mg/ml and 1 mg/ml packed volume respectively. These afforded adsorbents that had proteins and peptides at 2.4 and 0.5 mg/ml packed volume respectively.

Antisera to HbA were raised in goats, rabbits and outbred mice by a previously described immunization schedule (Atassi, 1967). The IgG fractions of these antisera, completely free of haptoglobin, were prepared as previously described (Gray *et al.*, 1969; Kazim & Atassi, 1980a). The pure IgG fractions were labelled with ^{125}I by a chloramine-T procedure (Hunter & Greenwood, 1962). The specific radioactivities of the labelled IgG fractions were 10–20 $\mu\text{Ci}/\mu\text{g}$.

The immunochemical activities of the protein and peptide fractions were determined by quantitative immuno-adsorbent titrations of fixed amounts of ^{125}I -labelled immune IgG and various amounts of peptide or protein adsorbents as previously described for myoglobin antigenic sites (Twining & Atassi, 1979). Non-specific adsorption was determined by titrating equivalent volumes of uncoupled Sepharose and bovine serum albumin–Sepharose under identical conditions. The values of ^{125}I -labelled immune IgG bound by the various adsorbents and reported in Table 2 were corrected for this non-specific binding.

Inhibition studies were employed to further

confirm the specificity of antibody binding to peptide adsorbents. In these studies, the appropriate adsorbents and labelled IgG fractions were allowed to react as above in the presence of either Hb (1 mg/ml) or an unrelated protein, bovine serum albumin (1 mg/ml). After correction for non-specific binding, the amount of radioactivity bound in the presence of Hb (inhibited values) was expressed as a percentage of that bound in the presence of bovine serum albumin (uninhibited values).

Specific antibodies were also isolated, and labelled with ^{125}I , on the peptide adsorbents (Matzku & Zoller, 1977). The activities of these peptide-specific antibodies were confirmed by binding studies with Hb, with α -chain, with the peptide-adsorbent originally employed for the isolation of the antibodies and in some cases with adsorbents of other peptides.

Results

Synthesis, purification and characterization of the peptides

The structures of the synthetic α -chain peptides are shown in Fig. 1. It should be noted that, since tryptophan is somewhat unstable under the acidic conditions used during synthesis, tryptophan-14 was replaced by phenylalanine in peptide 1–15 but not in peptide 11–25. The penultimate location of tryptophan in peptide 1–15 would have required its exposure to several additional acidic cycles than in peptide 11–25, which, it was feared, would result in an excessive accumulated loss. The substitution of tryptophan by phenylalanine in immunochemically active peptides has been shown to be permissible in previous studies on the antigenic structure of lysozyme (Lee *et al.*, 1976). Furthermore, tryptophan-14 is located in the overlapping region between peptides 1–15 and 11–25, and thus if phenylalanine were an unsuitable replacement for tryptophan any immunochemical activity due to this region would be detected by peptide 11–25. In addition, cysteine-104 was replaced by serine in peptides 91–105 and 101–115 in order to avoid difficulties associated with the oxidation of thiol groups (dimerization etc.).

After cleavage and deprotection, each peptide gave by ion-exchange chromatography a major chromatographic component that migrated as a single spot in high-voltage paper electrophoresis. That the major components were the desired products was confirmed by amino acid analysis. The results of the amino acid analyses of the deprotected and purified synthetic peptides are given in Table 1. The compositions found for these peptides agree well with the expected values. In peptide 81–95, however, there was a complete loss of proline. This may be attributed perhaps to the lability of this particular Asp–Pro peptide bond to acidic conditions such as the HBr/trifluoroacetic acid used to cleave the

| Peptide | |
|----------|---|
| 1-15: | Val-Leu-Ser-Pro-Ala-Asp-Lys-Thr-Asn-Val- <u>Lys-Ala-Ala-Phe-Gly</u> |
| 11-25: | <u>Lys-Ala-Ala-Trp-Gly-Lys-Val-Gly-Ala-His-Ala-Gly-Glu-Tyr-Gly</u> |
| 21-35: | <u>Ala-Gly-Glu-Tyr-Gly-Ala-Glu-Ala-Leu-Glu-Arg-Met-Phe-Leu-Ser</u> |
| 31-45: | <u>Arg-Met-Phe-Leu-Ser-Phe-Pro-Thr-Thr-Lys-Thr-Tyr-Phe-Pro-His</u> |
| 41-55: | <u>Thr-Tyr-Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val</u> |
| 51-65: | <u>Gly-Ser-Ala-Gln-Val-Lys-Gly-His-Gly-Lys-Lys-Val-Ala-Asp-Ala</u> |
| 61-75: | <u>Lys-Val-Ala-Asp-Ala-Leu-Thr-Asn-Ala-Val-Ala-His-Val-Asp-Asp</u> |
| 71-85: | <u>Ala-His-Val-Asp-Asp-Met-Pro-Asn-Ala-Leu-Ser-Ala-Leu-Ser-Asp</u> |
| 81-95: | <u>Ser-Ala-Leu-Ser-Asp-Leu-His-Ala-His-Lys-Leu-Arg-Val-Asp-Pro</u> |
| 91-105: | <u>Leu-Arg-Val-Asp-Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His-Ser-Leu</u> |
| 101-115: | <u>Leu-Ser-His-Ser-Leu-Leu-Val-Thr-Leu-Ala-Ala-His-Leu-Pro-Ala</u> |
| 111-125: | <u>Ala-His-Leu-Pro-Ala-Glu-Phe-Thr-Pro-Ala-Val-His-Ala-Ser-Leu</u> |
| 121-135: | <u>Val-His-Ala-Ser-Leu-Asp-Lys-Phe-Leu-Ala-Ser-Val-Ser-Thr-Val</u> |
| 131-141: | <u>Ser-Val-Ser-Thr-Val-Leu-Thr-Ser-Lys-Tyr-Arg</u> |

Fig. 1. Primary structures of the synthetic overlapping peptides of the α -chain

The numbers refer to the locations of residues in the α -chain. Regions that overlap with the preceding and following peptides are underlined. Note that Trp-14 is replaced by phenylalanine in peptide 1-15, and Cys-104 by serine in peptides 91-105 and 101-115. See the text for details.

peptide from the Merrifield resin. On the other hand, peptide 91-105, which contains the same Asp-Pro bond, gave the expected composition, indicating that this bond was unaffected by the identical procedures used in the preparation of this peptide. Possibly the C-terminal location of proline in peptide 81-95 might have contributed to the lability of this bond.

Binding studies of ^{125}I -labelled antibodies on protein and peptide adsorbents

In quantitative immunoabsorbent titrations of each of the ^{125}I -labelled immune IgG preparations [see Fig. 2 in Kazim & Atassi (1980b) for a representative titration], Hb-Sepharose invariably showed the highest immunochemical activity (Table 2). This is expected, since the antisera were prepared against Hb. At saturation (plateau values), the activities of the α -chain adsorbents were in the range 50-60% of those maximally attained by the Hb-adsorbent (Table 2). This indicates that, on immunization with Hb, antibodies capable of reacting with the α -chain are not particularly immunodominant over those reacting with the β -chain, at least in the representatives of the three animal

species studied. Further, their relative expression will probably vary somewhat even between animals of a given species. For example, the activity of the α -chain relative to Hb ranged from 51.4% to 61.8% for rabbits H-2 and R-91 respectively (Table 2). We have demonstrated (Krcó *et al.*, 1980, 1981a,b, 1982) that the immune responses in mice to the α - and β -chains of Hb are under separate genetic control. This is therefore an additional factor that will influence the relative expression of antibodies to the α - and β -chains. In the present studies, however, antisera from five outbred mice were pooled, and for these pooled antisera antibodies to both the α - and β -chain were present.

The titrations with immunoabsorbents of the synthetic peptides differentiated the peptides into two categories. With some peptides, the amount of radioactivity bound remained constant throughout the entire range of the titration. For these peptides, the amounts of ^{125}I -labelled antibody bound, after correction for non-specific binding, did not exceed 200 c.p.m. (Table 2) and were: for the goat antiserum, peptides 1-15, 21-35, 31-45, 61-75, 71-85, 91-105 and 131-141; for the rabbit and mouse antisera, peptides 1-15, 21-35, 31-45, 41-55,

Table 1. Summary of the results of amino acid analyses of the synthetic peptides. The values reported are the averages for three or more analyses. The expected values are shown in parentheses. The values of serine and threonine were obtained by extrapolation to zero hydrolysis time from 22 h, 48 h and 72 h hydrolyses.

| Amino acid | Amino acid composition (residues/molecule) | | | | | | | | | | | | | | |
|------------|--|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | Peptide ... | 1-15 | 11-25 | 21-35 | 31-45 | 41-55 | 51-65 | 61-75 | 71-85 | 81-95 | 91-105 | 101-115 | 111-125 | 121-135 | 131-141 |
| Asp | 2.08 (2) | | | | | 1.01 (1) | 0.98 (1) | 3.94 (4) | 3.93 (4) | 1.93 (2) | 1.97 (2) | 0.91 (1) | 1.01 (1) | 1.06 (1) | |
| Thr | 1.02 (1) | | | 2.95 (3) | 0.85 (1) | 0.90 (1) | | | | | | 0.91 (1) | 1.01 (1) | 0.92 (1) | 2.01 (2) |
| Ser | 0.83 (1) | | 0.87 (1) | 1.02 (1) | 1.85 (2) | 1.00 (1) | | 1.85 (2) | 1.79 (2) | 1.92 (2) | 1.95 (2) | 1.95 (2) | 0.96 (1) | 2.77 (3) | 2.89 (3) |
| Glu | | 1.04 (1) | 3.20 (3) | | 1.05 (1) | 1.12 (1) | | 0.96 (1) | 0 (1) | 1.13 (1) | 1.10 (1) | 1.07 (1) | 1.07 (1) | | |
| Pro | 1.10 (1) | | | 1.97 (2) | 0.92 (1) | | | | | | | 2.02 (2) | | | |
| Gly | 0.93 (1) | 4.20 (4) | 2.07 (2) | | 1.14 (1) | 3.13 (3) | | | | | | | | | |
| Ala | 3.10 (3) | 3.90 (4) | 2.95 (3) | | 1.06 (1) | 2.81 (3) | 4.11 (4) | 3.03 (3) | 2.00 (2) | | 3.10 (3) | 4.04 (4) | 2.14 (2) | | |
| Val | 1.98 (2) | 1.00 (1) | | | 0.85 (1) | 2.00 (2) | 3.04 (3) | 1.08 (1) | 1.12 (1) | 1.95 (2) | 0.98 (1) | 1.01 (1) | 2.87 (3) | 1.99 (2) | |
| Met | | | | 0.81 (1) | 1.12 (1) | | | 0.91 (1) | | | | | | | |
| Leu | 1.05 (1) | | 2.15 (2) | 0.97 (1) | 0.85 (1) | | 1.00 (1) | 1.92 (2) | 3.04 (3) | 4.20 (4) | 5.30 (5) | 2.04 (2) | 2.14 (2) | 1.00 (1) | 0.88 (1) |
| Tyr | | 0.95 (1) | 0.91 (1) | 0.98 (1) | 0.87 (1) | | | | | | | | 0.93 (1) | 0.97 (1) | |
| Phe | 0.92 (1) | | 0.94 (1) | 2.94 (3) | 2.10 (2) | | | | | | | | | 0.97 (1) | |
| His | | 1.10 (1) | | 0.95 (1) | 2.00 (2) | 0.94 (1) | 0.92 (1) | 0.90 (1) | 2.07 (2) | 0.91 (1) | 1.90 (2) | 2.18 (2) | 1.03 (1) | 1.08 (1) | |
| Lys | 1.97 (2) | 2.11 (2) | | 1.11 (1) | | 3.20 (3) | 1.10 (1) | | 0.97 (1) | 1.13 (1) | | | | | |
| Trp | | 0.95 (1) | | | | | | | | | | | | | |
| Arg | | | 0.95 (1) | 0.99 (1) | | | | | 0.93 (1) | 0.87 (1) | | | | 1.01 (1) | |

61-75, 71-85, 111-125 and 131-141. These peptides were considered to be inactive with these antisera. Alternatively, other peptides bound increasing amounts of radioactivity and the amounts of radioactivity bound by these peptides eventually levelled off at 'plateau' or maximum values. These peptides were clearly active and were: for the goat antiserum, peptides 11-25, 41-55, 51-65, 81-95, 101-115, 111-125 and 121-135; for the rabbit and mouse antisera: peptides 11-25, 51-65, 81-95, 91-105, 101-115 and 121-135. It should be noted that the titration curves for adsorbents of Hb and of the α -chain rose more sharply and attained a maximal value at lower amounts than those of the immuno-adsorbents of the peptides. This is consistent with the observation that peptides, even though active, will have predominantly random conformations and thus diminished affinities for their antibodies (Atassi & Saplin, 1968). Further, a considerable proportion of a peptide on the immuno-adsorbent is expected to have been rendered inactive owing to attachment of the peptide via side chains essential for binding with antibody, and to steric inaccessibility (Twining & Atassi, 1979; Atassi *et al.*, 1979). The binding of antibodies by these peptide-adsorbents, however, was completely inhibited by the addition of free uncoupled Hb to the reaction (results not shown). Furthermore, antibodies isolated on peptide-adsorbents bound only to peptide, Hb and α -chain, but did not bind to unrelated protein-adsorbent. These findings leave little doubt that antibodies reacting with the peptide adsorbents are specific for Hb.

It should be cautioned that the calculated sum of the activities of the peptides with each of the antisera is significantly larger than the activities of the α -chain itself. However, these results must be considered in the context of the structures of the peptides and their overlaps, which were designed to detect antigenic sites located in the overlapping regions between adjacent peptides (see the Discussion section). Thus adjacent overlapping peptides that have similar activities may be expressing identical specificities. The activities of overlapping peptides are therefore not additive. The activities of the peptides, and the localization of the antigenic sites that they represent, are considered in the Discussion section.

Discussion

Outline of the strategy

A key approach in the delineation of protein antigenic structures consists of immunochemical studies of overlapping peptide fragments obtained by chemical and enzymic cleavage of the parent protein (Atassi, 1972). This approach, when properly employed, can yield valuable information on the

Table 2. Summary of quantitative radioimmunoabsorption studies of ¹²⁵I-labelled IgG

The data here represent a summary of the 'plateau' values of the binding obtained from quantitative immuno-adsorbent titrations. The total amounts added of ¹²⁵I-labelled immune IgG of antisera G-2, H-2, R91 and M1-M5 were respectively 248 000, 430 000, 617 000, and 222 000 c.p.m.

Animal species in which anti-Hb antisera were raised ...

| Sephadex adsorbent | Goat (G2) | | Rabbit | | | | Mouse (M1-M5*) | |
|--------------------|--|-------------------------------|--|-------------------------------|--|-------------------------------|--|-------------------------------|
| | ¹²⁵ I-labelled anti-Hb bound (c.p.m.) | Reaction relative to α = 100% | H-2 | | R-91 | | ¹²⁵ I-labelled anti-Hb bound (c.p.m.) | Reaction relative to α = 100% |
| | | | ¹²⁵ I-labelled anti-Hb bound (c.p.m.) | Reaction relative to α = 100% | ¹²⁵ I-labelled anti-Hb bound (c.p.m.) | Reaction relative to α = 100% | | |
| Hb | 19 278 | — | 46 339 | — | 36 635 | — | 26 876 | — |
| α-chain | 11 721 | 100 | 23 818 | 100 | 22 671 | 100 | 17 008 | 100 |
| 1-15 | <200 | <1.7 | <200 | <0.8 | <200 | <0.9 | <200 | <1.2 |
| 11-25 | 670 | 5.7 | 4032 | 16.9 | 3341 | 14.7 | 4859 | 28.6 |
| 21-35 | <200 | <1.7 | <200 | <0.8 | <200 | <0.9 | <200 | <1.2 |
| 31-45 | <200 | <1.7 | <200 | <0.8 | <200 | <0.9 | <200 | <1.2 |
| 41-55 | 1455 | 12.4 | <200 | <0.8 | <200 | <0.9 | <200 | <1.2 |
| 51-65 | 1678 | 14.3 | 521 | 2.2 | <200 | <0.9 | 542 | 3.2 |
| 61-75 | <200 | <1.7 | <200 | <0.8 | <200 | <0.9 | <200 | <1.2 |
| 71-85 | <200 | <1.7 | <200 | <0.8 | <200 | <0.9 | <200 | <1.2 |
| 81-95 | 3958 | 33.8 | 2159 | 9.1 | 2273 | 10.0 | 1964 | 11.5 |
| 91-105 | <200 | <1.7 | 4505 | 18.9 | 3748 | 16.5 | 5249 | 30.9 |
| 101-115 | 1011 | 8.6 | 4144 | 17.4 | 4933 | 21.8 | 4509 | 26.5 |
| 111-125 | 3303 | 28.2 | <200 | <0.8 | <200 | <0.9 | <200 | <1.2 |
| 121-135 | 3043 | 26.0 | 15 185 | 63.8 | 22 971 | 101.3 | 15 736 | 92.5 |
| 131-141 | <200 | <1.7 | <200 | <0.8 | <200 | <0.9 | <200 | <1.2 |

* This is a pool of antisera from five outbred mice that had been immunized with Hb.

number of antigenic sites, their locations and their relative contributions to the activity of the native protein (Atassi, 1972). However, the approach has many limitations, and these have been previously discussed in detail (Atassi, 1977). An alternative to the use of cleavage procedures for obtaining overlapping peptides is their synthesis. The advantages that can be realized from the synthesis of peptides for immunochemical studies have been previously discussed (Atassi, 1975, 1978; Kazim & Atassi, 1980b). Indeed, the use of synthetic peptides has been invaluable in the elucidation of the antigenic sites of myoglobin (Atassi, 1975), lysozyme (Atassi, 1978) and albumin (Atassi *et al.*, 1979), and was originally proposed as a separate approach for determining protein antigenic structures once the sites had been narrowed down to a conveniently small size (Atassi, 1975).

In each of these proteins the peptides were invariably designed to include residues that had been identified from chemical modification and fragmentation studies as being antigenically important. For haemoglobin, however, little or no information was available about its antigenically important residues or the locations of its antigenic sites.

Therefore we introduced a strategy (Kazim & Atassi, 1980b) for studying the antigenic structure of haemoglobin (or indeed any other protein) that involved the systematic dissection of the haemoglobin subunits by a series of overlapping synthetic peptides encompassing the entire structures of the α- and β-chains. It was considered that the sizes of the synthetic peptides should be consistent with the number of residues expected for an antigenic site [e.g. five to seven residues for myoglobin (Atassi, 1975) and lysozyme (Atassi, 1978)] as well as having a high probability of possessing most (or all) of a site should it happen to fall in the overlap region between adjacent peptides. Peptides consisting of 15 residues and overlapping at their N- and C-termini by five residues each with adjacent peptides were considered adequate for these purposes [Fig. 1; also see Fig. 1 in Kazim & Atassi (1980b) for a schematic representation of this synthetic strategy]. It should be mentioned that this approach is restricted to the localization of continuous antigenic sites [i.e. those whose reactivity can be preserved in a continuous portion of the polypeptide chain, e.g. myoglobin antigenic sites (Atassi, 1975)]. Discontinuous antigenic sites, such as those of lysozyme




Fig. 2. Schematic diagram of the α -chain, α -chain regions that have been extrapolated from the five antigenic sites of sperm-whale Mb, and the antigenic sites of the α -chain that were localized in the present work with goat, rabbit and mouse antisera to Hb

The numbers refer to the locations of the residues in the α -chain. The asterisk (*) indicates that, owing to differences in the sizes of the polypeptide chains of Mb and the α -subunit, the antigenic site Mb 145-151 does not really have a full structural counterpart in the α -chain. See the text for details.

(Atassi, 1978), will not be detected unless a given peptide possesses most of the residues of that site which make the major contribution to its binding energy.

Analysis of immunochemical activities of the peptides

The activities of the peptides in quantitative immunoadsorbent titrations were quite similar for the goat, rabbit and mouse antisera studied, there being an identical correspondence between the rabbit and mouse antisera (Table 2). This is consistent with our previous findings that the locations of protein antigenic sites have not been dependent on the immunized species (Kazim & Atassi, 1977b; Twining *et al.*, 1980). The observed variations in the relative expression among and within these animal species of antigenic sites represented by the α -chain peptides (Table 2) are not unusual (Atassi, 1975). The active peptides represent immunodominant (more than 1-2% of the antibodies) antigenic sites of the α -chain of Hb. Peptide 121-135 deserves particular attention, since its activity in some instances was virtually equal to that of the α -chain itself (R-91, M1-M5; Table 2). At present we have no satisfactory explanation for this high activity. It is pertinent, however, that this binding was fully inhibited by free α -chains, suggesting that, perhaps as a result of the manner in which they are immobilized, adsorbents of α -chains are incapable of binding their full complement of antibodies.

Peptides that were seemingly inactive in the titration assay (Table 2) were further studied by attempting to isolate from adsorbents of these peptides antibodies specific for Hb. By using large excesses of unlabelled immune IgG, traces of Hb-specific antibodies could be isolated from that of peptide 1-15. Although the amounts of these

antibodies were not quantified, they account for less than 1-2% of the specific antibodies, since no binding could be detected with this peptide in the titration assay. This indicates the presence of a trace antibody response directed to this region of the α -chain, and suggests that other apparently inactive regions of the α -chain may also be recognized by amounts of antibodies below the detection level of these methods. In previous studies on myoglobin (Atassi, 1975) and lysozyme (Atassi, 1978) a 'general background response' to regions between their respective antigenic sites was found to account for 0.1-1.4% of the total antibodies to these proteins. Similarly, Dean & Schechter (1979) have reported the isolation of a subpopulation of anti-Hb antibodies directed against the region α 129-141, but which represents less than 1% of the total anti-Hb antibodies. Also, Takagaki *et al.* (1980) have reported the detection of antibodies to a continuous region of hen egg-white lysozyme (residues 38-54) that account for about 0.1-1% of the total anti-lysozyme antibodies. Thus the presence of trace antibody responses to regions interspersed among immunodominant sites would appear to be a general phenomenon for protein antigens. Although the regulation of the relative immunodominance of antigenic sites in proteins is poorly understood, the methodology for producing monoclonal antibodies introduced by Kohler & Milstein (1975) should permit amplification *in vitro* of what would ordinarily constitute trace antibody responses *in vivo*. The specificities and regulation of such responses could then be more readily studied.

Localization of the antigenic sites on the α -chain

For localizing antigenic sites within an active peptide we consider antigenic sites to consist of seven residues, and for a peptide to bind antibodies

of that specificity it must possess at least five of the seven site residues. Of course, exceptions to this rule can be expected where the absence of a single residue may abolish reactivity altogether. Similar activities of adjacent peptides may be due to antigenic sites lying in their overlapping regions. Accordingly, five antigenic sites on the α -chain that are recognized by goat, rabbit and mouse antisera to Hb were tentatively assigned to reside within, but not necessarily include all of, the general regions shown in Fig. 2. The site within region 12–24 recognized by goat antisera can be further localized to the region 15–23 since we had previously confirmed the presence of an antigenic site in this region by using goat antisera to Hb (Kazim & Atassi, 1977a). It should be kept in mind that the precise boundaries of these sites have not as yet been determined, and they are intentionally enlarged here in order to increase the probability of a correct assignment. Further studies with synthetic peptides overlapping within the assigned regions are required to determine the boundaries. Upon such refinement of the data, however, small shifts in the boundaries of these sites should not be unexpected (Koketsu & Atassi, 1973, 1974; Atassi, 1975).

Inspection of the three-dimensional structure of Hb (Perutz *et al.*, 1968; Fermi, 1975) reveals that three of the five antigenic sites localized here for the α -chain contain residues that participate in α_1 - β_1 (sites 4 and 5) or α_1 - β_2 (site 3) subunit interactions, and are therefore potentially obstructed in the Hb dimer and tetramer. This indicates that the immune recognition of the Hb occurs, at least in major part, at the level of its individual subunits. Our studies on the genetic control in mice of the immune response to Hb (Krco *et al.*, 1980, 1981a,b, 1982) have shown that the immune response to the α - and β -subunits in Hb are under separate genetic control. However, it has been reported (Tan-Wilson *et al.*, 1976; Crowley *et al.*, 1980) that a minor subpopulation of antibodies can occur in goat antisera to Hb that binds only to Hb (probably the $\alpha\beta$ -dimer) and not to either of the isolated subunits. It is likely therefore that, on immunization, Hb is recognized predominantly at the level of individual subunits and to a much smaller degree in higher states of subunit association.

Previous attempts, with Hb variants, to localize the antigenic sites of Hb resulted in the tentative identification of only two regions, around residues 15 and 16 and residue 68, as contributing to antigenic sites on the α -chain (Reichlin, 1975). In the present analysis, residues 15 and 16 lie within a localized antigenic site. Residue 68, however, does not fall within any of the localized antigenic sites. At this level of delineation we cannot exclude the possibility that residues outside of the regions assigned to the antigenic sites but in close spatial

proximity to the sites in the native α -chain influence, to various degrees, their reactivities. In this context, we have described (Atassi & Kazim, 1980; Kazim & Atassi, 1980c) antigenic sites as existing in a steric and electronic equilibrium with neighbouring residues, and their reactivities will therefore be affected by changes or perturbations in these environmental residues (Twining *et al.*, 1980).

Structural inherency of antigenic sites

We have previously mentioned that we were able, by extrapolation of the conformational location of Mb antigenic site 1 (Mb15–22), to predict and confirm by synthesis two antigenic sites (α 15–23 and β 16–23) on Hb (Kazim & Atassi, 1977a). Subsequent to these studies and to our proposal of structurally inherent antigenic sites (Atassi & Kazim, 1978), the antigenic structure of Mb (Atassi, 1975) was extrapolated to the conformationally similar soya-bean leghaemoglobin molecule (Hurrell *et al.*, 1978). Each of the extrapolated regions were found to be immunochemically active with an antiserum to leghaemoglobin. It was of interest then to compare the locations of the antigenic sites localized here for the α -chain with those precisely determined for the Mb molecule (Atassi, 1975). A structural extrapolation of the five antigenic sites of Mb to the α -chain indicates that the regions 15–22, 51–56, 88–93, 107–113 and 139–141 occupy conformational locations analogous to the five Mb antigenic sites: 15–22, 56–62, 94–99, 113–119 and 145–151. There is almost a complete coincidence, in terms of their locations, of the localized α -chain antigenic sites with the regions extrapolated from Mb (Fig. 2). With the exception of the region 139–141, all of the regions extrapolated from Mb fall within the localized antigenic sites on the α -chain.

These observations give overwhelming support to our proposal for the structural inherency of antigenic sites in a family of proteins (Atassi & Kazim, 1978). Other evidence has recently been reviewed in detail (Atassi, 1980). The term 'structurally inherent antigenic sites' was used to refer to antigenic sites whose antigenicities were determined by the uniqueness of their conformational locations, and could be present on immunochemically unrelated members of a protein family. The α -chain is 12 residues shorter than Mb, and therefore site 5 (region 145–151) of Mb does not have a counterpart in the α -chain. However, it should also be noted that antigenic site 5 on the α -chain does not have a counterpart antigenic site in Mb. We have previously cautioned that new antigenic sites, unique to Hb and its α - and β -chains, and without counterparts in the Mb molecule, should not be unexpected (Kazim & Atassi, 1977a). Clearly, unique shape and structural factors in a given protein may also

contribute to the recognition and selection of new antigenic sites.

The work was supported by Grant AM-18920 from the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, U.S. Public Health Service. A. L. K. is supported by a post-doctoral fellowship from the Muscular Dystrophy Association. We thank Mr. Duane Richardson and Mr. Todd Daniels for their expert technical assistance.

References

- Atassi, M. Z. (1964) *Biochem. J.* **93**, 189–197
- Atassi, M. Z. (1967) *Biochem. J.* **102**, 478–487
- Atassi, M. Z. (1972) in *Specific Receptors of Antibodies, Antigens and Cells* (Pressman, D., Tomasi, T. B., Grossberg, A. L. & Rose, N. R., eds.), pp. 118–136, S. Karger, Basel
- Atassi, M. Z. (1975) *Immunochemistry* **12**, 423–438
- Atassi, M. Z. (1977) in *Immunochemistry of Proteins* (Atassi, M. Z., ed.), vol. 1, pp. 1–161, Plenum Press, New York
- Atassi, M. Z. (1978) *Immunochemistry* **15**, 909–936
- Atassi, M. Z. (1980) *Mol. Cell. Biochem.* **32**, 21–44
- Atassi, M. Z. & Kazim, A. L. (1978) in *Immunobiology of Proteins and Peptides* (Atassi, M. Z. & Stavitsky, A. B., eds.), vol. 1, pp. 19–40, Plenum Press, New York
- Atassi, M. Z. & Kazim, A. L. (1980) *Biochem. J.* **187**, 163–172
- Atassi, M. Z. & Saplin, B. J. (1968) *Biochemistry* **7**, 688–698
- Atassi, M. Z., Sakata, S. & Kazim, A. L. (1979) *Biochem. J.* **179**, 327–331
- Braunitzer, G., Gehring-Muller, R., Hilschmann, N., Hilse, K., Hobom, G., Rudoff, V. & Wittman-Liebold, B. (1961) *Hoppe-Seyler's Z. Physiol. Chem.* **325**, 283–286
- Bucci, E. & Fronticelli, C. (1965) *J. Biol. Chem.* **240**, 551–552
- Crowley, J. B., Birkmeyer, R. C. & Tan-Wilson, A. L. (1980) *Immunochemistry* **17**, 1449–1457
- Dean, J. & Schechter, A. N. (1979) *J. Biol. Chem.* **254**, 9185–9193
- Fermi, G. (1975) *J. Mol. Biol.* **97**, 237–256
- Geraci, G., Parkhurst, L. F. & Gibson, Q. H. (1969) *J. Biol. Chem.* **244**, 4664–4667
- Gray, G. D., Mickelson, M. M. & Crim, J. A. (1969) *Immunochemistry* **6**, 641–644
- Hill, R. J. & Konigsberg, W. J. (1962) *J. Biol. Chem.* **237**, 3151–3156
- Hunter, W. M. & Greenwood, F. C. (1962) *Nature (London)* **194**, 495–496
- Hurrell, J. G. R., Smith, J. & Leach, S. J. (1978) *Immunochemistry* **15**, 297–302
- Kazim, A. L. & Atassi, M. Z. (1977a) *Biochem. J.* **167**, 275–278
- Kazim, A. L. & Atassi, M. Z. (1977b) *Biochim. Biophys. Acta* **494**, 277–282
- Kazim, A. L. & Atassi, M. Z. (1980a) *Biochem. J.* **185**, 285–287
- Kazim, A. L. & Atassi, M. Z. (1980b) *Biochem. J.* **191**, 261–264
- Kazim, A. L. & Atassi, M. Z. (1980c) *Biochem. J.* **191**, 673–680
- Kohler, G. & Milstein, C. (1975) *Nature (London)* **256**, 495–497
- Koketsu, J. & Atassi, M. Z. (1973) *Biochim. Biophys. Acta* **328**, 289–302
- Koketsu, J. & Atassi, M. Z. (1974) *Immunochemistry* **11**, 1–8
- Krco, C. J., Kazim, A. L., Atassi, M. Z. & David, C. S. (1980) *Abstr. Int. Congr. Immunol.* **4th** Abstr. 5.6.08
- Krco, C. J., Kazim, A. L., Atassi, M. Z. & David, C. S. (1981a) *J. Immunogenet.* **8**, 315–322
- Krco, C. J., Kazim, A. L., Atassi, M. Z. & David, C. S. (1981b) *J. Immunogenet.* **8**, 395–404
- Krco, C. J., Kazim, A. L., Atassi, M. Z. & David, C. S. (1982) *J. Immunogenet.* in the press
- Lee, C.-L., Pai, R.-C. & Atassi, M. Z. (1976) *Immunochemistry* **13**, 681–687
- Liu, T.-Y. & Chang, Y. H. (1971) *J. Biol. Chem.* **246**, 2842–2848
- March, S. C., Parikh, I. & Cuatrecasas, P. (1974) *Anal. Biochem.* **60**, 149–152
- Matzku, S. & Zoller, M. (1977) *Immunochemistry* **14**, 367–371
- Merrifield, R. B. (1963) *J. Am. Chem. Soc.* **85**, 2149–2154
- Perutz, M. F., Muirhead, H., Cox, J. M. & Goaman, L. C. G. (1968) *Nature (London)* **219**, 131–139
- Reichlin, M. (1975) *Adv. Immunol.* **20**, 71–123
- Stewart, J. M. & Young, J. D. (1969) *Solid Phase Peptide Synthesis*, pp. 1–103, W. H. Freeman, San Francisco
- Takagaki, Y., Hirayama, A., Fujio, H. & Amano, T. (1980) *Biochemistry* **19**, 2498–2505
- Tan-Wilson, A. L., Reichlin, M. & Noble, R. W. (1976) *Immunochemistry* **13**, 491–498
- Twining, S. S. & Atassi, M. Z. (1979) *J. Immunol. Methods* **30**, 139–151
- Twining, S. S., Lehmann, H. & Atassi, M. Z. (1980) *Biochem. J.* **191**, 681–697